Pages that link to "Q46107145"

The following pages link to Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers (Q46107145):

Displaying 24 items.

• Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies (Q26799714) (← links)
• Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data (Q31033443) (← links)
• Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma (Q33388581) (← links)
• Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. (Q33390549) (← links)
• Second-line systemic treatment for advanced cholangiocarcinoma (Q34484299) (← links)
• The molecular targets for the diagnosis and treatment of pancreatic cancer (Q34494019) (← links)
• A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). (Q35583855) (← links)
• A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer (Q36795363) (← links)
• Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials (Q37032865) (← links)
• Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? (Q37617955) (← links)
• Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. (Q37866791) (← links)
• Second-line chemotherapy in advanced biliary cancer: a systematic review (Q38207456) (← links)
• Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure (Q38577917) (← links)
• Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer (Q38694488) (← links)
• Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. (Q40860251) (← links)
• Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion (Q42194464) (← links)
• Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor (Q43198689) (← links)
• A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. (Q45903506) (← links)
• Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms (Q47335980) (← links)
• Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. (Q48333251) (← links)
• Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. (Q53579614) (← links)
• Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? (Q58799265) (← links)
• A Retrospective Study of S-1 Monotherapy as Second-line Treatment for Patients with Advanced Biliary Tract Cancer (Q84607738) (← links)
• Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option (Q89257709) (← links)